Curr Dir Autoimmun. 2008;10:258-79 Scleroderma. Authors: Gilliam AC The prototypic autoimmune diseases involving skin (lupus, dermatomyositis) typically result in epithelial injury and autoantibodies to characteristic cellular antigens. Disease-specific autoantibodies are also found in scleroderma, but scleroderma is different from other cutaneous autoimmune diseases because epithelial injury does not occur. Multiple…

2010 Jan;16(1 Suppl):S48-56 Hematopoietic cell transplantation for autoimmune disease: updates from Europe and the United States. Sullivan KM, Muraro P, Tyndall A Abstract Considerable advances have been made in our understanding of the immunobiology of autoimmune disease and its treatment with hematopoietic cell transplantation (HCT). In autoimmune disorders, the reconstituted…

2009 Jul;16(4):285-91 Adult stem cell transplantation in autoimmune disease. Tyndall A, Gratwohl A PURPOSE OF REVIEW: This review presents the recent results of a decade’s experience with hematopoietic stem cell transplantation for treating severe autoimmune disease, with special reference to new insights into pathophysiology. In addition, the newly evolving field…

Stem Cells and the FDA

As an associate member of the Cell Surgical Network (CSN), we conduct patient-funded research with neutral expectation of any particular outcome.

Stromal vascular fraction derived stem cells are not a recognized treatment or therapy for any known disease or disorder.

The Cell Surgical Network is not offering stem cell therapy as a cure for any condition, disease, or injury. No statements or treatments on this website have been evaluated or approved by the FDA. This website contains no medical advice. All statements and opinions provided by this website are provided for educational and informational purposes only and we do not diagnose or treat via this website or via telephone. Cell Surgical Network is offering patient funded research to treat individual patients with their own autologous stem cells and CSN is not involved in the use or manufacture of any investigational drugs.

CSN does not claim that any applications, or potential applications, using these autologous stem cell treatments are approved by the FDA, or are even effective. We do not claim that these treatments work for any listed nor unlisted condition, intended or implied. It’s important for potential patients to do their own research based on the options that we present so that one can make an informed decision. Any decision to participate in our patient funded experimental protocols is completely voluntary.

ATTENTION: If you have ANY concern with our autologous stem cell treatment product, methods, website, or technique and think we may be violating any U.S. law, please contact us so that we can investigate the matter or concern immediately.